KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Total Current Liabilities (2016 - 2025)

Amgen has reported Total Current Liabilities over the past 17 years, most recently at $25.5 billion for Q4 2025.

  • Quarterly results put Total Current Liabilities at $25.5 billion for Q4 2025, up 10.35% from a year ago — trailing twelve months through Dec 2025 was $25.5 billion (up 10.35% YoY), and the annual figure for FY2025 was $25.5 billion, up 10.35%.
  • Total Current Liabilities for Q4 2025 was $25.5 billion at Amgen, up from $21.8 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for AMGN hit a ceiling of $25.5 billion in Q4 2025 and a floor of $12.2 billion in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $17.0 billion (2023), compared with a mean of $17.6 billion.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 49.12% in 2021 and later decreased 13.49% in 2022.
  • Amgen's Total Current Liabilities stood at $12.2 billion in 2021, then increased by 28.75% to $15.7 billion in 2022, then grew by 17.24% to $18.4 billion in 2023, then rose by 25.59% to $23.1 billion in 2024, then increased by 10.35% to $25.5 billion in 2025.
  • The last three reported values for Total Current Liabilities were $25.5 billion (Q4 2025), $21.8 billion (Q3 2025), and $20.5 billion (Q2 2025) per Business Quant data.